Department of Clinical Pharmacology, Medical University of Vienna, Austria.
Pharmacologie cellulaire et moléculaire, Université catholique de Louvain, Brussels, Belgium.
J Antimicrob Chemother. 2020 Sep 1;75(9):2650-2656. doi: 10.1093/jac/dkaa176.
The antibiotic temocillin has recently been rediscovered as a promising therapeutic option against MDR Gram-negative bacteria. However, some aspects of the pharmacokinetic (PK) profile of the drug are still to be elucidated: subcutaneous administration of temocillin might be of interest as an alternative to the intravenous route in selected patients. Similarly, information on the penetration of temocillin into human soft tissues is lacking.
To investigate the feasibility and plasma PK of subcutaneous dosing as well as soft tissue PK of temocillin after intravenous administration to healthy volunteers.
Eight healthy volunteers received 2 g of temocillin both as intravenous and subcutaneous infusion in a randomized two-period crossover study. Concentration-time profiles of total temocillin in plasma (after both routes) and of unbound temocillin in plasma, muscle and subcutis (only after intravenous dosing) were determined up to 12 h post-dose.
Subcutaneous dosing caused some infusion site discomfort but resulted in sustained drug concentrations over time with only slightly decreased overall exposure compared with intravenous dosing. Plasma protein binding of temocillin showed concentration-dependent behaviour and was higher than previously reported. Still, unbound drug concentrations in muscle and subcutis determined by microdialysis markedly exceeded those in plasma, suggesting good tissue penetration of temocillin.
The subcutaneous administration of temocillin is a valid and feasible alternative to intravenous dosing. With the description of plasma protein binding and soft tissue PK of temocillin in healthy volunteers, this study provides important information that adds to the ongoing characterization of the PK profile of temocillin and might serve as input for PK/PD considerations.
抗生素替莫西林最近被重新发现是一种有前途的治疗耐多药革兰氏阴性菌的治疗选择。然而,该药物的一些药代动力学(PK)特征仍有待阐明:替莫西林的皮下给药可能是一种替代静脉途径的选择,适用于某些患者。同样,关于替莫西林渗透进入人体软组织的信息也缺乏。
研究替莫西林在健康志愿者中的皮下给药的可行性和血浆 PK 以及静脉给药后的软组织 PK。
8 名健康志愿者在一项随机两周期交叉研究中分别接受 2g 替莫西林静脉和皮下输注。在给药后 12 小时内,测定替莫西林在血浆中的总浓度-时间曲线(两种途径)以及在血浆、肌肉和皮下组织中的游离替莫西林浓度-时间曲线(仅在静脉给药后)。
皮下给药会引起一些输注部位不适,但随着时间的推移,药物浓度持续,与静脉给药相比,总体暴露量仅略有下降。替莫西林的血浆蛋白结合表现出浓度依赖性,且高于先前报道的水平。然而,通过微透析测定的肌肉和皮下组织中的游离药物浓度明显高于血浆中的浓度,表明替莫西林有良好的组织穿透性。
替莫西林的皮下给药是静脉给药的有效且可行的替代方法。本研究描述了替莫西林在健康志愿者中的血浆蛋白结合和软组织 PK,为该药物 PK 特征的不断表征提供了重要信息,并可能为 PK/PD 考虑提供依据。